Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Variation characteristics and clinical significance of TP53 in patients with myeloid neoplasms.

Hematology (Amsterdam, Netherlands) - 1 Dec 2024

Ma Qiang, Liu Yan, Zhao Hong, Guo Yixian, Sun Wanling, Hu Ronghua

Abstract excerpt

Objectives: MDS and AML characterized by TP53 variations have a poor prognosis in general. However, specifically, differences in prognosis have also been observed in patients with different TP53 variants and VAFs.Methods: Here, we retrospectively analyzed datasets of patients with MDS, MPN, and AML who underwent targeted DNA sequencing from February 2018 to December 2023, and patients with reportable TP53...

Topics

Join the communities discussing this publication.

Aged
Aged, 80 and over
Clinical Relevance
Leukemia, Myeloid, Acute
Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Myelodysplastic Syndromes

Tumor Suppressor Protein p53

Source

Identifiers

PMID: 39140716
DOI: 10.1080/16078454.2024.2387878

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Variation characteristics and clinical significance of TP53 in patients with myeloid neoplasms.PMID 39140716Read ↗

TP53 in MDS and AML: Biological and clinical advances.Semantic proximity Read ↗

Clinical and molecular characteristics of acute myeloid leukemia and the dismal prognosis of TP53 mutations in a real-world setting.Semantic proximity Read ↗

Comparative outcome and prognostic factor analysis among MDS/AML patients with TP53 mutations, snps, and wild type.Semantic proximity Read ↗

Overall survival in TP53-mutated AML and MDS.Semantic proximity Read ↗

TP53 in AML and MDS: The new (old) kid on the block.Semantic proximity Read ↗

Genetic and Clinical Features in TP53-Mutated Patients With Myelodysplastic Neoplasms: A Retrospective Study Based on Next-Generation Sequencing Data.Semantic proximity Read ↗

The prognostic impact of variant allele frequency (VAF) in TP53 mutant patients with MDS: A systematic review and meta-analysis.Semantic proximity Read ↗

Comparison of TP53 mutations in myelodysplasia and acute leukemia suggests divergent roles in initiation and progressionSemantic proximity Read ↗

Clinical implications of subclonal TP53 mutations in acute myeloid leukemiaSemantic proximity Read ↗

Clinical interrogation of TP53 aberrations and its impact on survival in patients with myeloid neoplasmsSemantic proximity Read ↗

[Clinical and prognostic values of TP53 mutation in patients with acute myeloid leukemia].Semantic proximity Read ↗

TP53 mutation variant allele frequency of ≥10% is associated with poor prognosis in therapy-related myeloid neoplasms.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.